|Bid||0.00 x 2200|
|Ask||0.00 x 900|
|Day's Range||3.82 - 4.78|
|52 Week Range||0.60 - 5.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.13|
TransEnterix Inc (NYSEMKT:TRXC), a medical equipment company based in United States, saw a significant share price rise of over 20% in the past couple of months on the AMEX. WithRead More...
Biotech stocks are also capitalizing on AI’s potential to deliver revolutionary drugs and speed up drug discovery. “I believe that AI is a sleeping giant for healthcare in general,” Eric Horvitz, director of Microsoft Research Labs, said earlier this year.
NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ally ...
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. Today's attention is redirected to the Medical Instruments and Supplies space, which comprises companies that manufacture and sell medical devices, instrument systems, and reagents and consumables.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company filed a FDA 510(k) submission for additional Senhance System instruments including 3 millimeter diameter instruments. The clearance of these instruments would allow the Senhance to be used for microlaparoscopic surgeries, allowing surgeons to make tiny incisions that are deemed virtually scarless for patients. “TransEnterix is the first company to seek FDA clearance for robotically-driven 3 millimeter instruments for abdominal surgery in the U.S.,” said Todd M. Pope, TransEnterix CEO.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on TransEnterix, Inc. (NYSE: TRXC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TRXC as the Company's latest news hit the wire. On May 29, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for expanded indications of the Company's Senhance Surgical System for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that LSU Health completed the purchase of the Company’s Senhance™ Surgical System. The Senhance has been installed at University Medical Center New Orleans (UMC New Orleans). UMC New Orleans is home to the Reverend Avery C. Alexander Academic Research Hospital, and is an academic medical center in partnership with LSU Health New Orleans, Tulane University School of Medicine, and other local colleges and universities.
Transenterix Inc (NYSE: TRXC ) announced Tuesday that its laparoscopic Senhance Surgical System was approved by the FDA for two additional indications. What Happened The Senhance Surgical System received ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Momo Inc (ADR) (NASDAQ: MOMO ) was trading higher ...
TransEnterix Inc. shares surged 12% in premarket trade Tuesday, after the company said it has won U.S. Food and Drug Administration approval for expanded indications for its Senhance Surgical System. Specifically, the company said the FDA has cleared the medical device company for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery. "There are approximately 760,000 inguinal hernia and 1.2 million laparoscopic cholecystectomy procedures performed annually in the U.S.," the company said.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Company has received FDA 510(k) clearance for expanded indications of its Senhance Surgical System. The Company received FDA 510(k) clearance for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery.
TransEnterix, Inc. (NYSE American: TRXC) (the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it has entered into a debt financing agreement with Hercules Capital, Inc., as administrative agent and collateral agent (“Hercules”), and the banks and financial institutions entering into the loan agreement, to provide the Company with up to $40.0 million in term loans.
Management at the robotic surgery upstart has laid out its game plan for the year ahead. Here are the must-know details for shareholders.
Traders cheer after the company reports upbeat first quarter results and shares some good news. Here are the key takeaways for investors.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 8) CONMED Corporation (NASDAQ: CNMD ) Enanta Pharmaceuticals Inc ...
On a per-share basis, the Morrisville, North Carolina-based company said it had a loss of less than 1 cent. Losses, adjusted for non-recurring gains, came to 6 cents per share. The maker of surgical robots ...